Stock listing

BOATS:SLN Silence Therapeutics PLC Stock

US listing (BOATS) of Silence Therapeutics PLC · home listing NASDAQ:SLN

Follow Silence Therapeutics PLC into a list and get an email when it puts out news.

Home listing price · NASDAQ:SLN

$19.81 USD -0.01 (-0.1%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SLN

Past year +212.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$19.80 – $19.83 USDNov 20, 2026
Volume
399,148 sharesNov 20, 2026
Market cap
$1.23B USDAt the close on Nov 20, 2026 · price × 62.20M shares outstanding
52-week range
$4.19 – $19.87 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$42.19M USDMedian day 958,192 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Silence Therapeutics PLC logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SLN · Home$19.81 USD-0.01 (-0.1%)399,148$19.81$19.83$19.80$19.82Close on Nov 20, 2026
OTC:SLNCF$6.527 USD+0.171 (+2.7%)221$6.527$6.527$6.527$6.355Close on Nov 12, 2026
Frankfurt:XRP2€17.90 EUR0.00 (0.0%)—€17.70€17.90€17.70€17.90Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SLN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$19.81-0.01-0.1%$19.81$19.83$19.80399,148
$19.82+0.02+0.1%$19.79$19.83$19.791,471,176
$19.800.000.0%$19.80$19.82$19.791,211,323
$19.80-0.03-0.2%$19.80$19.83$19.80625,258
$19.83+0.03+0.2%$19.78$19.86$19.76586,511
$19.80+0.03+0.2%$19.76$19.82$19.76659,203
$19.77-0.02-0.1%$19.80$19.81$19.77286,296
$19.79+0.04+0.2%$19.73$19.80$19.72827,879
$19.75+0.02+0.1%$19.72$19.76$19.701,377,348
$19.73+0.01+0.1%$19.75$19.77$19.72958,192
$19.72-0.08-0.4%$19.78$19.80$19.721,403,180
$19.80+0.02+0.1%$19.78$19.81$19.751,023,282
$19.78+0.02+0.1%$19.78$19.80$19.78352,414
$19.76+0.01+0.1%$19.75$19.80$19.751,186,300
$19.75-0.05-0.3%$19.74$19.80$19.74621,425
$19.80+0.09+0.5%$19.71$19.80$19.711,814,666
$19.71-0.07-0.4%$19.76$19.79$19.702,757,825
$19.780.000.0%$19.78$19.80$19.711,488,165
$19.78+0.11+0.6%$19.66$19.87$19.654,654,216
$19.67+0.01+0.1%$19.65$19.68$19.652,126,200
$19.66-0.01-0.1%$19.69$19.69$19.633,078,400
$19.67+0.06+0.3%$19.61$19.67$19.602,801,300
$19.61+0.03+0.2%$19.58$19.65$19.5713,961,900
$19.58+10.90+125.6%$19.59$19.61$19.5671,909,500
$8.68-0.67-7.2%$9.10$9.22$8.661,131,100
$9.35+0.37+4.1%$8.81$9.46$8.812,567,500
$8.98+0.11+1.2%$8.91$9.27$8.851,233,200
$8.87-0.78-8.1%$9.53$9.565$8.711,450,200
$9.65-0.21-2.1%$9.70$10.36$9.58551,000
$9.86+0.34+3.6%$9.45$10.39$9.45844,300
$9.52-0.30-3.1%$9.71$9.72$9.0551,109,600
$9.82-0.01-0.1%$9.77$10.14$9.601,319,600
$9.83-0.31-3.1%$10.12$10.19$9.631,583,400
$10.14-0.50-4.7%$10.62$10.65$10.05976,300
$10.64-0.07-0.7%$10.77$10.78$10.38973,300
$10.71-0.22-2.0%$10.98$11.05$10.491,578,900
$10.93+0.13+1.2%$10.85$11.30$10.651,356,300
$10.80-0.40-3.6%$11.19$11.26$10.76884,400
$11.20+0.02+0.2%$11.13$11.42$11.01710,700
$11.18-0.04-0.4%$11.25$11.47$11.03953,200
$11.22-0.29-2.5%$11.50$11.70$11.18691,400
$11.51-0.78-6.3%$12.21$12.35$11.06877,000
$12.29+0.04+0.3%$12.27$12.50$12.17382,100
$12.25+0.05+0.4%$12.39$12.44$12.03665,700
$12.20-0.50-3.9%$12.59$12.74$12.141,141,900
$12.70+0.20+1.6%$12.76$13.00$12.57690,500
$12.50+0.04+0.3%$12.53$12.78$12.24983,800
$12.46-0.60-4.6%$13.11$13.11$12.101,383,400
$13.06+0.04+0.3%$12.95$13.28$12.721,095,300
$13.02-0.29-2.2%$13.32$13.42$12.88685,900
$13.31-0.24-1.8%$13.38$13.81$13.04682,600
$13.55-0.14-1.0%$13.60$14.00$13.36645,900
$13.69-0.90-6.2%$14.24$14.47$13.401,351,800
$14.59-0.20-1.4%$14.63$14.79$14.42611,200
$14.790.000.0%$14.85$15.09$14.45572,400
$14.79+0.05+0.3%$14.70$15.28$14.10634,200
$14.74+1.21+8.9%$13.49$14.89$13.261,134,900
$13.53+0.11+0.8%$13.39$13.65$13.09478,200
$13.42-0.03-0.2%$13.46$13.69$13.18539,700
$13.45-0.08-0.6%$13.47$13.69$13.36283,600
$13.53-0.14-1.0%$13.68$13.68$13.36301,700
$13.67+0.38+2.9%$13.31$13.99$13.31645,000
$13.29+0.02+0.2%$13.37$13.59$13.05723,700
$13.27+0.10+0.8%$13.17$13.48$13.13740,600
$13.17-0.44-3.2%$13.50$13.57$13.01585,200
Ticker
BOATS:SLN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
BOATS
Currency
USD

What changed lately

Latest news

All Silence Therapeutics PLC news

Silence Therapeutics PLC on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 3 in all · newest Nov 12, 2026 · oldest 2026
Calls
5 calls with a replay · 5 with a transcript · latest Feb 27, 2025
Decks
40 decks · latest Aug 10, 2026

Where Silence Therapeutics PLC is listed

ListingExchangeCountryCurrency
NASDAQ:SLN · Home listingNASDAQUnited StatesUSD
OTC:SLNCFOTCUnited StatesUSD
gettex:XRP2gettexGermanyEUR
LS Exchange:A2QB4JLS ExchangeGermanyEUR
Frankfurt:XRP2FrankfurtGermanyEUR
Tradegate:XRP2TradegateGermanyEUR
Stuttgart:XRP2StuttgartGermanyEUR
Munich:XRP2MunichGermanyEUR
Dusseldorf:XRP2DusseldorfGermanyEUR
Lang & Schwarz:A2QB4JLang & SchwarzGermanyEUR
BOATS:SLN · This pageBOATSUnited StatesUSD

Valuation

EV/sales 2,159× against a median of 15.4×: the highest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$984.6M USD
P/E
Loss
EV/sales
2,159×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
5.7×
Gross margin
95.0%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.07

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Silence Therapeutics PLC · NASDAQ:SLNUS$1.23BUS$984.6Mn/a2,159×n/a5.7×n/a0.0×1.07
Avalyn Pharma Inc. · NASDAQ:AVLNUS$1.26BUS$946.4Mn/an/an/a3.4×n/a0.0×0.12
LB Pharmaceuticals Inc · NASDAQ:LBRXUS$1.26BUS$858.7Mn/an/an/a3.0×n/a0.0×0.81
MannKind Corporation · NASDAQ:MNKDUS$1.24BUS$1.46Bn/a3.5×309×n/a−18.1%n/a1.06
Novavax, Inc. · NASDAQ:NVAXUS$1.23BUS$902.3Mn/a2.2×n/an/a−18.6%n/a1.98
Ocular Therapeutix, Inc. · NASDAQ:OCULUS$1.23BUS$774.9Mn/a15.4×n/a2.8×−648.6%0.2×1.35
Generate Biomedicines, Inc. · NASDAQ:GENBUS$1.22BUS$895.6Mn/a28.1×n/a3.2×−637.0%0.2×1.90
Taysha Gene Therapies, Inc. · NASDAQ:TSHAUS$1.21BUS$837.4Mn/a153×n/a3.4×n/a0.1×1.69
Mineralys Therapeutics, Inc. · NASDAQ:MLYSUS$1.21BUS$585.1Mn/an/an/a2.4×n/a0.0×1.39
GH Research PLC · NASDAQ:GHRSUS$1.20BUS$841.0Mn/an/an/a3.4×n/a0.0×1.28
Vor Biopharma Inc. · NASDAQ:VORUS$1.18BUS$697.4M0.9×n/an/an/an/an/a1.25
Median of the othersUS$1.23BUS$849.9M0.9×15.4×309×3.2×−327.8%0.0×1.32

Forecasts

1 strong buy · 4 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
19.75 USD · Analysts' mean
EPS, year to Dec 2026
-0.37 · 1 analyst
Revenue, year to Dec 2026
314.9K · 7 analysts

Team and board

Officers

OfficerRole
Rhonda HellumsExecutive Vice President, Chief Financial Officer
Jaimin B. ShahSVP, General Counsel
Steven RomanoExecutive Vice President, Chief Research and Development Officer
Curtis RambaranChief Medical Officer
Iain RossInterim Principal Executive Officer
Marie Wikström LindholmChief Scientific Officer

Board

DirectorRole
Iain RossInterim Principal Executive Officer
Dave LemusNon-Executive Director
James Ede-GolightlyNon-Executive Director
Rhonda HellumsExecutive Vice President, Chief Financial Officer
Tim McInerneyNon-Executive Director

Events

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open+0.1%
Q2 2026Aug 10, 2026 · Before open+29.1%
Q1 2026May 20, 2026+12.5%
Q4 2025Mar 5, 2026 · Before open−4.8%
Q3 2025Nov 6, 2025 · Before open+3.4%
Q2 2025Aug 7, 2025 · Before open+1.1%
Q1 2025May 8, 2025 · Before open−3.8%
Q4 2024Feb 27, 2025−5.7%
Q3 2024Nov 14, 2024 · Before open−8.3%
Q2 2024Aug 15, 2024 · Before open+3.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024+7.3%
Q4 2023Mar 13, 2024 · Before open−1.1%
Q3 2023Nov 14, 2023 · Before open+2.3%
Q2 2023Aug 16, 2023 · Before open+6.2%
Q1 2023May 16, 2023−7.2%
Q4 2022Mar 15, 2023−6.9%
Q3 2022Nov 10, 2022+10.7%
Q2 2022Sep 14, 2022−1.7%
Q1 2022May 16, 2022−1.8%
Q4 2021Mar 17, 2022−0.8%

Open Events

Decks

DeckKindSlidesDate
Technical Presentation (August 2026)Technical21 slidesAug 10, 2026
Corporate Update (August 2026)Corporate update21 slidesAug 10, 2026
Investor Presentation (June 2026)Investor deck38 slidesJun 23, 2026
Investor Presentation (March 2026)Investor deck41 slidesMar 5, 2026
FY2024 Earnings PresentationEarnings23 slidesFeb 27, 2025
Investor Presentation (September 2024)Investor deck35 slidesSep 5, 2024
Investor Presentation (July 2024)Investor deck33 slidesJuly 2024
Technical Presentation (June 2024)Technical22 slidesJun 27, 2024
Investor Presentation (January 2023)Investor deck36 slidesJanuary 2023
Investor Presentation (November 2022)Investor deck34 slidesNov 16, 2022
All 40 decks
DeckKindSlidesDate
Investor Presentation (October 2022)Investor deck36 slidesOctober 2022
RBC Capital Markets Global Healthcare Conference 2021Conference16 slidesMay 19, 2021
Investor Presentation (May 2021)Investor deck32 slidesMay 19, 2021
H1 2020 Earnings PresentationEarnings12 slidesSep 14, 2020
FY2019 Earnings PresentationEarnings8 slidesApr 14, 2020
Annual Needham Healthcare Conference 2020Conference31 slidesApril 2020
Corporate Update (March 2020)Corporate update9 slidesMar 25, 2020
Cowen Healthcare Conference 2020Conference35 slidesMar 2, 2020
Investor Day (September 2019)Investor day134 slidesSep 12, 2019
39th Annual Cowen Health Care Conference 2019Conference27 slidesMar 11, 2019
Cantor Fitzgerald Global Healthcare Conference 2018Conference20 slidesOct 3, 2018
H1 2018 Earnings PresentationEarnings13 slidesSeptember 2018
The Oligo Meeting 2018 - OTS Seattle 2018Conference16 slidesAug 1, 2018
European Hematology Association (EHA) Congress 2018Conference13 slidesJun 14, 2018
2018 BIO International ConventionConference19 slidesJune 2018
TIDES: Oligonucleotide and Peptide Therapeutics 2018Conference36 slidesMay 7, 2018
9th Clinical Trials Innovation Programme 2018Conference36 slidesApr 26, 2018
Oligo Oxford 2018Conference36 slidesApr 10, 2018
OPT Congress 2018Conference32 slidesMar 28, 2018
OPT Congress 2018Conference38 slidesMar 27, 2018
Cowen 38th Annual Health Care Conference 2018Conference22 slidesMar 13, 2018
FY2017 Earnings PresentationEarnings40 slidesMar 6, 2018
AsiaTIDES 2018Conference44 slidesMar 1, 2018
JP Morgan Healthcare Conference 2018Conference35 slidesJanuary 2018
14th International Conference on Thalassaemia & Haemoglobinopathies (November 2017)Conference9 slidesNov 19, 2017
Investor Day (November 2017)Investor day95 slidesNov 14, 2017
37th Annual Canaccord Genuity Growth Conference 2017Conference17 slidesAugust 2017
TIDES: Oligonucleotide and peptide therapeutics 2017Conference21 slidesMay 2, 2017
AsiaTIDES Kyoto 2017Conference17 slidesFeb 23, 2017
EuroTides 2016Conference16 slidesNov 15, 2016

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue559.0K43.3M31.6M21.7M12.4M5.48M244.0K016.0K770.0K
Cost of revenue215.0K11.8M12.9M13.5M7.46M3.76M9.74M7.94M8.71M
Gross profit344.0K31.4M18.8M8.19M4.96M1.72M244.0K-9.74M-7.93M-7.94M
Research and development67.8M67.9M56.9M43.5M30.8M20.2M13.3M9.74M7.94M8.71M
Selling, general and administrative20.0M14.0M9.64M10.8M6.46M3.96M
Operating income-91.1M-63.3M-64.4M-61.0M-45.8M-35.8M-22.7M-20.6M-14.4M-11.9M
Depreciation and amortization312.0K336.0K369.0K379.0K425.1K496.0K482.0K399.0K433.0K310.0K
EBITDA-90.8M-63.0M-64.0M-60.7M-45.4M-35.4M-22.3M-20.2M-14.0M-11.6M
Interest expense8.00K16.0K33.0K45.0K15.0K1.54M
Income before tax-88.6M-44.5M-53.3M-49.6M-45.9M-36.0M-22.9M-20.5M-3.77M-10.4M
Income tax11.0K845.0K956.0K688.0K-6.45M-3.49M-3.29M-2.12M-2.16M-1.92M
Net income-88.6M-45.3M-54.2M-50.3M-39.4M-32.5M-19.6M-18.4M-1.62M-8.44M
Earnings per share, basic-0.63-0.33-0.49-0.52-1.33-1.19-0.78-0.79-0.07-0.36
Earnings per share, diluted-0.63-0.33-0.49-0.52

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents11.3M121.3M68.8M73.5M27.4M13.5M21.5M42.7M39.0M
Short-term investments73.8M26.0M010.0M20.0M5.04M319.0K3.00K
Receivables0972.0K290.0K331.0K29.3M4.00K2.45M2.00M810.0K
Inventory11.49M-2.45M-2.48M-2.99M
Current assets118.7M187.4M103.2M86.3M76.4M37.5M29.5M45.5M42.0M
Property, plant and equipment1.58M1.82M1.94M1.94M1.13M611.0K921.0K1.17M1.38M
Goodwill10.6M9.39M9.98M9.68M7.59M8.13M7.69M8.13M8.03M7.71M
Total assets131.4M202.6M119.4M96.2M86.0M46.1M38.9M55.0M55.8M
Accounts payable4.07M2.29M1.79M1.15M462.0K528.0K
Current liabilities13.6M16.8M22.3M15.2M25.6M9.65M3.83M2.66M1.61M
Total debt137.0K341.0K287.0K
Total liabilities69.1M68.6M97.5M87.7M76.9M25.2M3.83M2.66M1.61M
Shareholders' equity62.3M134.0M22.0M27.2M8.53M9.06M20.9M35.1M52.4M54.2M
Shares outstanding141.7M141.7M118.8M107.8M29.7M27.3M25.0M23.4M23.3M23.3M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-62.3M-67.6M-49.5M-57.0M9.19M-10.8M1.73M-16.8M-9.60M-10.1M
Capital spending-55.0K-211.0K-56.0K-173.0K-1.80M-514.0K-9.00K-188.0K-173.0K-537.0K
Free cash flow-62.3M-67.9M-49.5M-57.2M7.39M-11.3M1.72M-16.9M-9.77M-10.6M
Cash from investing-48.0M-22.0M19.3M-20.5M11.7M9.62M-15.0M-4.83M13.0M-4.67M
Cash from financing15.0K142.1M31.9M52.6M41.4M15.4M5.27M341.0K48.0K-101.0K
Share buybacks00-101.0K
Change in cash-110.2M52.5M1.77M-25.0M62.2M13.9M-7.98M-21.3M3.73M-12.9M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 12, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialNov 12, 2026Meeting noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeNov 5, 2026Big-stake noticeSEC
DEFA14A · Additional proxy materialOct 19, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialOct 19, 2026Meeting noticeSEC
8-K · Current reportOct 19, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 13, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeOct 13, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
8-K · Current reportAug 12, 2026Material contractSEC
424B5 · ProspectusAug 12, 2026Offer documentSEC
S-3MEFAug 11, 2026Other filingsSEC
424B5 · ProspectusAug 10, 2026Offer documentSEC
8-K · Current reportAug 10, 2026Current reportSEC
10-Q · Quarterly reportAug 10, 2026Quarterly reportSEC
8-K · Current reportAug 10, 2026ResultsSEC
8-K/A · Current report, amendedJul 16, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 8, 2026Big-stake noticeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Current reportSEC
8-K · Current reportJun 16, 2026Meeting outcomeSEC
8-K · Current reportJun 11, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMay 28, 2026Other filingsSEC
424B5 · ProspectusMay 27, 2026Offer documentSEC
CORRESP · Letter to the SECMay 22, 2026Other filingsSEC
UPLOAD · Letter from the SECMay 22, 2026Other filingsSEC
8-K · Current reportMay 18, 2026Material contractSEC
S-3 · Registration statementMay 18, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 29, 2026Annual reportSEC
DEF 14A · Proxy statementApr 29, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansMar 5, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
UPLOAD · Letter from the SECJan 9, 2026Other filingsSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
CORRESP · Letter to the SECDec 31, 2025Other filingsSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
4 · Change in ownershipDec 22, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 22, 2025Insider tradeSEC
8-K/A · Current report, amendedDec 22, 2025Management or board changeSEC
8-K · Current reportDec 22, 2025Management or board changeSEC
UPLOAD · Letter from the SECDec 18, 2025Other filingsSEC
8-K · Current reportDec 15, 2025Management or board changeSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
8-K · Current reportNov 6, 2025ResultsSEC
8-K · Current reportOct 23, 2025Current reportSEC
8-K · Current reportAug 14, 2025Management or board changeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipAug 4, 2025Insider tradeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
4 · Change in ownershipJul 23, 2025Insider tradeSEC
4 · Change in ownershipJul 16, 2025Insider tradeSEC
4 · Change in ownershipJul 10, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
8-K · Current reportJun 27, 2025Meeting outcomeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 25, 2025Big-stake noticeSEC
4 · Change in ownershipJun 25, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipMay 29, 2025Insider tradeSEC
4 · Change in ownershipMay 27, 2025Insider tradeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 20, 2025Insider tradeSEC
ARS · Annual report to shareholdersMay 16, 2025Annual reportSEC
DEF 14A · Proxy statementMay 16, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 8, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
4 · Change in ownershipMay 8, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementMay 6, 2025Meeting noticeSEC
8-K · Current reportMay 6, 2025Management or board changeSEC
4 · Change in ownershipMay 2, 2025Insider tradeSEC
10-K/A · Annual report, amendedApr 30, 2025Annual reportSEC
4 · Change in ownershipApr 30, 2025Insider tradeSEC
4 · Change in ownershipApr 28, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 24, 2025Big-stake noticeSEC
4 · Change in ownershipApr 24, 2025Insider tradeSEC
4 · Change in ownershipApr 22, 2025Insider tradeSEC
4 · Change in ownershipApr 15, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 31, 2025Big-stake noticeSEC
4 · Change in ownershipMar 31, 2025Insider tradeSEC
4 · Change in ownershipMar 6, 2025Insider tradeSEC
S-8 · Registration statement for employee plansFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
8-K · Current reportFeb 27, 2025ResultsSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 11, 2025Big-stake noticeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
4 · Change in ownershipJan 6, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 2, 2025Insider tradeSEC
8-K · Current reportJan 2, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 20, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerDec 9, 2024Current reportSEC
6-K · Report of a foreign issuerNov 18, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerNov 14, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
F-3ASROct 22, 2024Other filingsSEC
6-K · Report of a foreign issuerAug 15, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedAug 2, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerJun 27, 2024Current reportSEC
6-K · Report of a foreign issuerJun 24, 2024Current reportSEC
6-K · Report of a foreign issuerJun 20, 2024Current reportSEC
6-K · Report of a foreign issuerMay 17, 2024Current reportSEC
6-K · Report of a foreign issuerMay 16, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveMay 15, 2024Other filingsSEC
424B3 · ProspectusMay 14, 2024Offer documentSEC
CORRESP · Letter to the SECMay 10, 2024Other filingsSEC
UPLOAD · Letter from the SECMay 10, 2024Other filingsSEC
DEL AMMay 8, 2024Other filingsSEC
F-3 · Registration statementMay 7, 2024Offer documentSEC
6-K · Report of a foreign issuerMay 1, 2024Current reportSEC
6-K · Report of a foreign issuerApr 29, 2024Current reportSEC
6-K · Report of a foreign issuerApr 15, 2024Current reportSEC
SC 13D/A · Big-stake notice, amendedMar 27, 2024Big-stake noticeSEC
20-F · Annual reportMar 13, 2024Annual reportSEC
6-K · Report of a foreign issuerMar 13, 2024Current reportSEC
6-K · Report of a foreign issuerFeb 23, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 5, 2024Current reportSEC
6-K · Report of a foreign issuerDec 1, 2023Current reportSEC
6-K · Report of a foreign issuerNov 14, 2023Current reportSEC
6-K · Report of a foreign issuerNov 1, 2023Current reportSEC
SC 13G · Big-stake noticeSep 1, 2023Big-stake noticeSEC
6-K/A · Report of a foreign issuer, amendedAug 29, 2023Current reportSEC
6-K · Report of a foreign issuerAug 16, 2023Current reportSEC
SC 13D/A · Big-stake notice, amendedAug 14, 2023Big-stake noticeSEC
S-8 · Registration statement for employee plansAug 1, 2023Offer documentSEC
6-K · Report of a foreign issuerJul 11, 2023Current reportSEC
6-K · Report of a foreign issuerJul 3, 2023Current reportSEC
6-K · Report of a foreign issuerMay 16, 2023Current reportSEC
6-K · Report of a foreign issuerMay 4, 2023Current reportSEC
6-K · Report of a foreign issuerMay 1, 2023Current reportSEC
6-K · Report of a foreign issuerApr 27, 2023Current reportSEC
6-K · Report of a foreign issuerMar 28, 2023Current reportSEC
20-F · Annual reportMar 15, 2023Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 8, 2023Big-stake noticeSEC
6-K · Report of a foreign issuerJan 12, 2023Current reportSEC
6-K · Report of a foreign issuerNov 10, 2022Current reportSEC
6-K · Report of a foreign issuerNov 7, 2022Current reportSEC
SC 13D/A · Big-stake notice, amendedOct 20, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerSep 29, 2022Current reportSEC
SC 13G · Big-stake noticeAug 22, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeAug 19, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerAug 16, 2022Current reportSEC
424B5 · ProspectusAug 12, 2022Offer documentSEC
6-K · Report of a foreign issuerAug 12, 2022Current reportSEC
6-K · Report of a foreign issuerAug 11, 2022Current reportSEC
SC 13D/A · Big-stake notice, amendedJul 20, 2022Big-stake noticeSEC
SC 13D · Big-stake noticeJun 15, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerJun 14, 2022Current reportSEC
6-K · Report of a foreign issuerMay 16, 2022Current reportSEC
6-K · Report of a foreign issuerMay 16, 2022Current reportSEC
6-K · Report of a foreign issuerApr 25, 2022Current reportSEC
6-K · Report of a foreign issuerApr 4, 2022Current reportSEC
6-K · Report of a foreign issuerMar 23, 2022Current reportSEC
20-F · Annual reportMar 17, 2022Annual reportSEC
6-K · Report of a foreign issuerFeb 22, 2022Current reportSEC
SC 13G · Big-stake noticeFeb 14, 2022Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 14, 2022Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 10, 2022Big-stake noticeSEC
6-K · Report of a foreign issuerFeb 9, 2022Current reportSEC
SC 13G · Big-stake noticeFeb 7, 2022Big-stake noticeSEC

This page holds 200 of 280 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Silence Therapeutics PLC’s releases

Common shares
62,203,024
Fully diluted
62,203,024

Fully diluted

LineShares
Common shares62,203,024

Share count over time

CountShares
Nov 22, 202662,203,024

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Fidelity4.71M2.5%US$51.5MSep 30, 2026
Siren, L.L.C.2.89M1.5%US$31.6MSep 30, 2026
Citadel2.83M1.5%US$30.9MSep 30, 2026
Redmile Group, LLC2.46M1.3%US$26.9MSep 30, 2026
Tetragon Partners GP Ltd2.44M1.3%US$26.6MSep 30, 2026
Soleus Capital Management, L.P.2.39M1.3%US$26.1MSep 30, 2026
Balyasny Asset Management L.P.2.25M1.2%US$24.6MSep 30, 2026
Squadron Capital Management LLC2.08M1.1%US$22.8MSep 30, 2026
TCG Crossover Management, LLC1.82M0.97%US$19.9MSep 30, 2026
Morgan Stanley1.76M0.94%US$19.2MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Nextech Invest Ltd.1.69M0.91%US$18.5MSep 30, 2026
Millennium1.45M0.78%US$15.9MSep 30, 2026
BNP Paribas1.17M0.63%US$12.8MSep 30, 2026
Nantahala Capital Management, LLC1.16M0.62%US$12.7MSep 30, 2026
Qube Research & Technologies Ltd1.06M0.57%US$11.6MSep 30, 2026
Ameriprise1.04M0.56%US$11.3MSep 30, 2026
Ikarian Capital, LLC822K0.44%US$3.29MSep 30, 2026
Susquehanna821K0.44%US$8.97MSep 30, 2026
Persistent Asset Partners Ltd782K0.42%US$782KSep 30, 2026
Montanova Capital, LLC741K0.40%US$8.1MSep 30, 2026
Rtw Investments, LP700K0.38%US$7.65MSep 30, 2026
KVP Capital Advisors, LP684K0.37%US$7.48MSep 30, 2026
Two Sigma680K0.36%US$7.43MSep 30, 2026
ADAR1 Capital Management, LLC630K0.34%US$6.88MSep 30, 2026
UBS610K0.33%US$6.66MSep 30, 2026
Caption Management, LLC519K0.28%US$5.67MSep 30, 2026
TD486K0.26%US$5.31MSep 30, 2026
5AM Venture Management, LLC476K0.26%US$5.2MSep 30, 2026
Goldman Sachs463K0.25%US$5.06MSep 30, 2026
Affinity Asset Advisors, LLC450K0.24%US$4.92MSep 30, 2026
Lombard Odier Asset Management (Europe) Ltd424K0.23%US$4.63MSep 30, 2026
Acuta Capital Partners, LLC394K0.21%US$4.3MSep 30, 2026
Alyeska Investment Group, L.P.365K0.20%US$3.99MSep 30, 2026
Seven Fleet Capital Management LP350K0.19%US$3.83MSep 30, 2026
BlackRock331K0.18%US$3.61MSep 30, 2026
Woodline Partners LP300K0.16%US$3.28MSep 30, 2026
Fred Alger Management, LLC250K0.13%US$2.73MSep 30, 2026
Seven Grand Managers, LLC250K0.13%US$2.73MSep 30, 2026
Fortress Investment Group LLC230K0.12%US$2.51MSep 30, 2026
Cantor Fitzgerald, L. P.218K0.12%US$2.38MSep 30, 2026
Sofinnova Investments, Inc.212K0.11%US$2.31MSep 30, 2026
abrdn206K0.11%US$2.25MSep 30, 2026
BMO201K0.11%US$2.2MSep 30, 2026
Boothbay Fund Management, LLC201K0.11%US$2.19MSep 30, 2026
Nomura200K0.11%US$2.18MSep 30, 2026
Barclays196K0.11%US$2.14MSep 30, 2026
Jane Street193K0.10%US$2.11MSep 30, 2026
Ishara Investments LP160K0.09%US$1.75MSep 30, 2026
Renaissance Technologies152K0.08%US$1.66MSep 30, 2026
Squarepoint Ops LLC148K0.08%US$1.61MSep 30, 2026

This page holds 50 of 91 holders. Open Shareholders

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Michael Davidson
Other companies: BioAge Labs, Inc. (Independent Director · Since at least Mar 26, 2024); NewAmsterdam Pharma Company N.V. (Chief Executive Officer · Since at least Dec 29, 2023); Tenax Therapeutics, Inc. (Board Director · Since at least Feb 25, 2021); Lisata Therapeutics, Inc. (Director · Jul 28, 2020 – Jan 10, 2022 · Past); Omthera Pharmaceuticals Inc (Executive VP & CMO · Apr 11, 2013 – Jul 18, 2013 · Past)
Director · Jan 2, 2025 – Jan 2, 2025 · Past
Steven J Romano
Other companies: Dianthus Therapeutics, Inc. (Director · Since at least Sep 16, 2024); Mallinckrodt Inc (EVP & Chief Sci. Ofcr · Jun 16, 2022 – Jun 16, 2022 · Past)
EVP and Chief R&D Officer · Since at least Jan 2, 2025
Rhonda Hellums
Other companies: Aratana Therapeutics Inc (CHIEF FINANCIAL OFFICER · Feb 1, 2019 – Jul 18, 2019 · Past)
Executive Vice President, Chief Financial Officer · Since at least Jan 2, 2025
Curtis RambaranChief Medical Officer · Since at least Nov 5, 2026
Dave LemusNon-Executive Director · Since at least Nov 4, 2026
David LemusDirector · Since at least Jan 2, 2026
Iain RossInterim Principal Executive Officer · Since at least Oct 19, 2026
Jaimin B. ShahSVP, General Counsel · Since at least Nov 5, 2026
James Ede-GolightlyNon-Executive Director · Since at least Nov 4, 2026
Marie Wikström LindholmChief Scientific Officer · Since at least Nov 5, 2026
All 13 people
PersonSeat
Steven RomanoExecutive Vice President, Chief Research and Development Officer · Since at least Nov 4, 2026
Tim McInerneyNon-Executive Director · Since at least Nov 4, 2026
Timothy McInerneyDirector · Since at least May 5, 2025

Open People

Log in to ask 6ix AI your own questions about Silence Therapeutics PLC.